# Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales
Canonical URL: https://biopharmsignal.com/news/CNTA/acquisition-of-centessa-by-lilly-approved-by-the-high-court-of-justice-of-england-and-wales
Ticker: CNTA
Company: Centessa Pharmaceuticals
Source: Centessa Pharmaceuticals
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.centessa.com
## Summary

BOSTON and LONDON, June 22, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, which entered into a definitive agreement on March 31,

## Article Body
BOSTON and LONDON, June 22, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, which entered into a definitive agreement on March 31,
## Recent Company News
- 2026-06-25 13:46 EST — [Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales](https://biopharmsignal.com/news/CNTA/acquisition-of-centessa-by-lilly-approved-by-the-high-court-of-justice-of-england-and-wales) — Source: Centessa Pharmaceuticals
- 2026-06-25 13:46 EST — [Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025](https://biopharmsignal.com/news/CNTA/centessa-pharmaceuticals-reports-financial-results-and-business-highlights-for-the-second-quarter-of-2025) — Source: Centessa Pharmaceuticals
- 2026-06-25 13:46 EST — [Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference](https://biopharmsignal.com/news/CNTA/centessa-pharmaceuticals-to-participate-in-the-morgan-stanley-23rd-annual-global-healthcare-conference) — Source: Centessa Pharmaceuticals
- 2026-06-25 13:46 EST — [Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program](https://biopharmsignal.com/news/CNTA/centessa-pharmaceuticals-reports-financial-results-for-the-third-quarter-of-2025-and-provides-update-on-potential-best-in-class-orexin-receptor-2-ox2r-agonist-program) — Source: Centessa Pharmaceuticals
- 2026-06-25 13:46 EST — [Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares](https://biopharmsignal.com/news/CNTA/centessa-pharmaceuticals-announces-proposed-public-offering-of-american-depositary-shares) — Source: Centessa Pharmaceuticals
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)